Well, when a CEO with his intimate history with the company resigns and they release this boilerplate "pusuing other opportunities" BS, you know something major happened. The real question IMO is whether there were big differnce between the CEO and BOD regarding how to move the company forwards or if this company is as good as sold.
other than a general (20-20) hindsight that essentially said... wished we had not combined 320 and 184 w/o doing preclinical work on the combination.
Mayers did say the 320 - 184 combo was probably DOA. IDIX still working to get clinical hold cleared... IDIX showed more on other PI's in the discovery phase...
Market Data 
Markets 
AI
